30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now

VIKING GLOBAL INVESTORS LP

Track

Insider profile

Performance

Overall performance
3.2
Performance over holding periods
4.2
30 days 90 days 120 days
Average return -5% 8.2% 15.1%
Success rate 27% 68% 82%
Transactions
55 20% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance
Performance for realised trades
4.4
Average return 48%
Success rate 73%
Average holding period 220
Transactions 28
Ranking by realised performance
VIKING GLOBAL INVESTORS LP's trades of Inhibrx Biosciences Inc's stock


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2025-10-09 2025-10-07
S Sale
4,175 -4.1%
377.09
US$3,634,988 		4,175 -4.1% 377.09 US$3,634,988
2025-10-09 2025-10-07
S Sale
76,763 -39.5%
202.56
US$1,828,321 		76,763 -39.5% 202.56 US$1,828,321
2025-10-09 2025-10-07
S Sale
37,493 -30.9%
304.61
US$993,308 		37,493 -30.9% 304.61 US$993,308
2025-07-01 2025-06-27
S Sale
3,500,000 -15.9%
44.00
US$154,000,000 		3,500,000 -15.9% 44.00 US$154,000,000
2025-01-31 2025-01-31
PrS Proposed sale
3,065,616
34.90
US$106,989,998 		3,065,616 34.90 US$106,989,998
2025-01-31 2025-01-31
S Sale
3,065,616 -12.2%
34.90
US$106,989,998 		3,065,616 -12.2% 34.90 US$106,989,998
2024-06-18 2024-06-17
S Sale
39,032 -100.0%
38.15
US$1,489,071 		39,032 -100.0% 38.15 US$1,489,071
2024-06-18 2024-06-17
S Sale
1,912,750 -100.0%
38.15
US$72,971,412 		1,912,750 -100.0% 38.15 US$72,971,412
2024-06-18 2024-06-17
S Sale
39,032 -100.0%
38.15
US$1,489,071 		39,032 -100.0% 38.15 US$1,489,071
2024-06-18 2024-06-17
S Sale
1,912,750 -100.0%
38.15
US$72,971,412 		1,912,750 -100.0% 38.15 US$72,971,412
2024-03-07 2024-03-05
S Sale
60,772 -60.9%
34.25
US$2,081,441 		60,772 -60.9% 34.25 US$2,081,441
2024-03-07 2024-03-05
S Sale
2,977,845 -60.9%
34.25
US$101,991,191 		2,977,845 -60.9% 34.25 US$101,991,191
2024-03-07 2024-03-05
S Sale
60,772 -60.9%
34.25
US$2,081,441 		60,772 -60.9% 34.25 US$2,081,441
2024-03-07 2024-03-05
S Sale
2,977,845 -60.9%
34.25
US$101,991,191 		2,977,845 -60.9% 34.25 US$101,991,191
2024-01-05 2024-01-04
S Sale
540,000 -11.3%
19.53
US$10,546,200 		540,000 -11.3% 19.53 US$10,546,200
2024-01-04 2024-01-02
S Sale
3,983 -18.9%
31.30
US$124,668 		3,983 -18.9% 31.30 US$124,668
2024-01-04 2024-01-02
S Sale
195,200 -18.9%
31.30
US$6,109,760 		195,200 -18.9% 31.30 US$6,109,760
2024-01-04 2024-01-02
S Sale
6,300,817 -18.9%
31.30
US$197,215,572 		6,300,817 -18.9% 31.30 US$197,215,572
2024-01-04 2024-01-02
S Sale
3,983 -18.9%
31.30
US$124,668 		3,983 -18.9% 31.30 US$124,668
2024-01-04 2024-01-02
S Sale
195,200 -18.9%
31.30
US$6,109,760 		195,200 -18.9% 31.30 US$6,109,760
2024-01-04 2024-01-02
S Sale
6,300,817 -18.9%
31.30
US$197,215,572 		6,300,817 -18.9% 31.30 US$197,215,572
2024-01-02 2024-01-02
PrS Proposed sale
6,500,000
32.88
US$213,720,000 		6,500,000 32.88 US$213,720,000
2023-09-21 2023-09-19
US RayzeBio Inc (RYZB)
B Purchase
458,333 +35.7%
18.00
US$8,249,994 		458,333 +35.7% 18.00 US$8,249,994
2023-09-21 2023-09-19
US RayzeBio Inc (RYZB)
B Purchase
930,556 +23.4%
18.00
US$16,750,008 		930,556 +23.4% 18.00 US$16,750,008
2023-09-21 2023-09-19
US RayzeBio Inc (RYZB)
B Purchase
458,333 +35.7%
18.00
US$8,249,994 		458,333 +35.7% 18.00 US$8,249,994
2023-09-21 2023-09-19
US RayzeBio Inc (RYZB)
B Purchase
930,556 +23.4%
18.00
US$16,750,008 		930,556 +23.4% 18.00 US$16,750,008
2023-08-30 2023-08-28
US Inhibrx Inc (INBX)
B Purchase
511,627 +inf%
19.35
US$9,899,982 		511,627 +inf% 19.35 US$9,899,982
2023-07-19 2023-07-18
S Sale
1,500,000 -5.6%
35.00
US$52,500,000 		1,500,000 -5.6% 35.00 US$52,500,000
2023-06-26 2023-06-22
S Sale
2,226,195 -14.7%
9.90
US$22,039,330 		2,226,195 -14.7% 9.90 US$22,039,330
2023-06-26 2023-06-22
S Sale
5,236,006 -14.7%
9.90
US$51,836,459 		5,236,006 -14.7% 9.90 US$51,836,459
2023-06-26 2023-06-22
S Sale
5,427,043 -14.7%
9.90
US$53,727,726 		5,427,043 -14.7% 9.90 US$53,727,726
2023-06-26 2023-06-22
S Sale
110,756 -14.7%
9.90
US$1,096,484 		110,756 -14.7% 9.90 US$1,096,484
2023-05-11 2023-05-09
B Purchase
850,000 +21.6%
16.00
US$13,600,000 		850,000 +21.6% 16.00 US$13,600,000
2022-11-04 2022-11-02
B Purchase
279,530 +30.0%
10.08
US$2,817,662 		279,530 +30.0% 10.08 US$2,817,662
2022-11-04 2022-11-02
B Purchase
567,532 +30.0%
10.08
US$5,720,723 		567,532 +30.0% 10.08 US$5,720,723
2022-10-12 2022-10-07
US Inhibrx Inc (INBX)
B Purchase
333,333 +inf%
30.00
US$9,999,957 		333,333 +inf% 30.00 US$9,999,957
2022-10-12 2022-10-07
US Inhibrx Inc (INBX)
B Purchase
1,000,000 +70.1%
30.00
US$29,999,900 		1,000,000 +70.1% 30.00 US$29,999,900
2022-09-09 2022-09-09
S Sale
3,142 -0.2%
31.44
US$98,792 		3,142 -0.2% 31.44 US$98,792
2022-09-09 2022-09-09
S Sale
73,886 -3.8%
30.90
US$2,282,804 		73,886 -3.8% 30.90 US$2,282,804
2022-09-09 2022-09-09
S Sale
147,502 -7.1%
29.87
US$4,405,545 		147,502 -7.1% 29.87 US$4,405,545
2022-09-09 2022-09-09
S Sale
6,654 -0.2%
31.44
US$209,218 		6,654 -0.2% 31.44 US$209,218
2022-09-09 2022-09-09
S Sale
156,463 -3.8%
30.90
US$4,834,128 		156,463 -3.8% 30.90 US$4,834,128
2022-09-09 2022-09-09
S Sale
312,353 -7.1%
29.87
US$9,329,266 		312,353 -7.1% 29.87 US$9,329,266
2022-09-09 2022-09-08
S Sale
52,466 -2.5%
32.23
US$1,690,958 		52,466 -2.5% 32.23 US$1,690,958
2022-09-09 2022-09-08
S Sale
7,554 -0.4%
30.59
US$231,058 		7,554 -0.4% 30.59 US$231,058